



Representative Legal Matters

Dr. iur. Julia Schieber

- Advised Numab Therapeutics on its USD 1.25 billion sale of its atopic dermatitis spin-off to Johnson & Johnson.
- Advised CureVac on its licensing deal with GSK for mRNA candidate vaccines for influenza and COVID-19 globally in consideration for EUR 400 million upfront and up to an additional EUR 1.05 billion in milestones as well as tiered royalties.
- Advised Galapagos on the intended transfer of its Jyseleca® business to Alfasigma, including the European and UK Marketing Authorizations, the commercial, medical and development activities for Jyseleca® and approximately 400 FTEs in 14 European countries.
- Advised Sino Biopharmaceutical on its partnership with Boehringer Ingelheim to bring innovative cancer therapies to China.
- Advised a global pharmaceutical company on a number of licensing and collaboration agreements.
- Advised GSK on its license agreement with WuXi Biologics for multiple novel bi- and multi-specific T cell engagers.
- Advised CureTeq on its licensing agreement with Merck for oncology asset M8891.
- Advised CureVac on its collaboration agreement with myNeo N.V. for identifying novel antigen targets for mRNA-based cancer vaccine development.
- Advised the founders of Digital Republic on selling the company to mobilezone Group.
- Advised Adagene on its collaboration with Sanofi for novel masked immuno-oncology antibody candidates.
- Advised several multinational pharma companies on advance purchase agreements with the EU Commission and European governments for the purchase of COVID-19 vaccines and treatments.
- Advised argenx in its strategic collaboration for efgartigimod in greater China, including USD 75 million in upfront Zai Lab equity and USD 100 million in near-term milestone and other payments.
- Advised MODAG GmbH on its license collaboration for a neurodegenerative disease drug candidate with Teva Pharmaceutical Industries Ltd.

- Advised CureVac AG on its COVID-19 collaboration and license agreement with GSK.
- Advised CureVac AG on its COVID-19 partnership agreement with Bayer AG.
- Advised Adagene AG on its collaboration and license agreement with Exelixis.
- Advised CureVac AG on its strategic mRNA technology collaboration with GSK in the field of infectious diseases.
- Advised Numab Therapeutics AG on a collaboration and license agreement with Boehringer Ingelheim.
- Advised CSL Behring on its strategic partnership with Thermo Fisher.
- Advised JobCloud AG on various IP, commercial and data protection related issues.
- Advised OnlineDoctor AG on various IP, commercial and data protection related issues.
- Advised Novaliq GmbH on a license agreement with Bausch Health.
- Advised Numab Therapeutics AG on a global research and option agreement with Eisai, Co., Ltd.
- Advised Novaliq GmbH on a license agreement with Jiangsu Hengrui Medicine.